NCT00660790 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Tripolt NJ, Meinitzer A, Eder M, Wascher TC, Pieber TR, Sourij H
Multifactorial risk factor intervention in patients with Type 2 diabetes improves arginine bioavailability ratios. Diabet Med. 2012 Oct;29(10):e365-8. doi: 10.1111/j.1464-5491.2012.03743.x.
Tripolt NJ, Narath SH, Eder M, Pieber TR, Wascher TC, Sourij H
Multiple risk factor intervention reduces carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol. 2014 May 23;13:95. doi: 10.1186/1475-2840-13-95.

Multifactorial Treatment of Cardiovascular Risk in Patients With Diabetes Mellitus Type-2: Identification of Treatment Non-Responders (The CARDIONOR Study)

Details for clinical trial NCT00660790

Clinical trial NCT00660790 - References